Use of cgrp antagonist compounds for treatment of psoriasis

Abstract

The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (CGRP) antagonistic effect. Methods are also disclosed for identifying compounds with CGRP antagonist activity which thereby are suitable candidate compounds for treating psoriasis.

1 . A method of treating or remedying psoriasis in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of at least one calcitonin gene-related peptide CGRP antagonist compound in a pharmaceutical acceptable formulation. 
     
     
         2 . The method according to  claim 1 , wherein the at least one CGRP antagonist compound is selected from the group consisting of 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazolinyl piperadine compounds, anti-CGRP antibodies, a peptide comprising SEQ ID NO:1, tryptase active polypeptide, BIBN4096BS, and heparin. 
     
     
         3 . The method according to  claim 1 , wherein the at least one CGRP antagonist compound is administered locally. 
     
     
         4 . (canceled) 
     
     
         5 . The method according to  claim 1 , wherein the CGRP antagonist compound is administered topically. 
     
     
         6 - 14 . (canceled) 
     
     
         15 . The method according to  claim 1 , wherein the at least one CGRP antagonist is administered topically, dermally, intradermally, subcutaneously, via dermal infusion, or via subcutaneous infusion. 
     
     
         16 . The method according to  claim 1 , wherein said at least one CGRP antagonist compound comprises a polypeptide of SEQ ID NO:1. 
     
     
         17 . The method according to  claim 1 , wherein said at least one CGRP antagonist compound consists essentially of a polypeptide of SEQ ID NO:1. 
     
     
         18 . The method according to  claim 1 , wherein the at least one CGRP antagonist compound is a CGRP peptide which lacks wild type CGRP activity and binds to CGRP receptor. 
     
     
         19 . The method according to  claim 1 , wherein the at least one CGRP antagonist is administered dermally, intradermally, subcutaneously, via dermal infusion, via subcutaneous infusion, or via microdialysis. 
     
     
         20 . The method according to  claim 1 , wherein the at least one CGRP antagonist compound is BIBN4096BS. 
     
     
         21 . The method according to  claim 1 , wherein the pharmaceutically acceptable formulation consists essentially of a CGRP antagonist and an excipient. 
     
     
         22 . The method according to  claim 1 , further comprising exposing the subject to UVB radiation and/or administering a cell division inhibitor to the subject.